Treatments for myelin disorders, such as multiple sclerosis, are largely confined to anti-inflammatory drugs, which often show limited effectiveness in only subgroups of patients. Combination therapies that target both inflammation and other processes, such as remyelination, might be of benefit in such disorders. In this article, Taveggia et al. provide an overview of the signaling pathways that regulate myelination and highlight how targeting such pathways might promote remyelination.
- Carla Taveggia
- Maria Laura Feltri
- Lawrence Wrabetz